A B S T R A C T

Background
Respiratory distress (RD) can occur in both preterm and term neonates born through normal vaginal delivery or caesarean section (CS). It accounts for about 30% of neonatal deaths and can occur at any time following birth. Respiratory distress syndrome (RDS), transient tachypnoea (rapid breathing) of the newborn and persistent pulmonary hypertension (increased blood pressure of pulmonary vessels) of the newborn are the most frequent clinical presentations of neonatal RD. Prostaglandins are used in routine obstetric practice to ripen the uterine cervix and to trigger labour, with those of the E series being preferred over others due to the fact that they are more uteroselective. Administration of prostaglandins to an expectant mother before delivery causes reabsorption of lung fluid from the fetal lung and promotes surfactant secretion by inducing a catecholamine surge. As a result, significant reduction in neonatal respiratory morbidity following a CS could be obtained, leading to reduced long-term complications such as bronchopulmonary dysplasia (chronic lung disease with lung tissue modification) and asthma.
Objectives
The objective of this review was to determine if administration of prostaglandins before CS can improve respiratory outcomes of newborns.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2013) . We also searched three clinical trial registries; ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry and the WHO Clinical Trials Registry Platform (ICTRP), for ongoing studies (24 June 2013).
Selection criteria
We included all published and unpublished randomised controlled trials comparing the use of prostaglandins with other treatments (including placebo) to reduce neonatal respiratory morbidity. Participants were pregnant women with an indication for a CS, and we compared administration of prostaglandins prior to CS with no treatment, placebo or another treatment.
Data collection and analysis
Two review authors independently assessed studies for inclusion and assessed trial quality, with the third review author referred to for settling any disagreements. Two review authors extracted data. Data were checked for accuracy. We used the Cochrane tool for assessing risk of bias in the included study and contacted the study authors to request additional information where appropriate.
Main results
We found one randomised controlled trial with a low risk of bias which was carried out in a tertiary neonatal care centre in Australia. The study involved 36 women (18 received intravaginal prostaglandin E 2 gel and 18 received placebo).
There was one case of neonatal respiratory distress in the control group, which the trialist reported as transient tachypnoea of the newborn (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 7.68, one study, n = 36).
None of the neonates required mechanical ventilation and the trial authors reported median Apgar scores at one and five minutes as being similar in both groups.
There were no treatment-related side effects in either group. Noradrenaline concentrations (median values (range)) were reported as being significantly higher in the cord blood samples of the intervention group compared to the control group.
Authors' conclusions
Although the trial authors reported a significant increase in catecholamine levels in the intervention group, there was no significant difference in the respiratory outcomes between intervention and control groups. The quality of evidence was graded as low because the sample size was small and there were few events. No definite conclusions can thus be drawn on the effects of prostaglandins on neonatal respiratory outcomes from this review.
P L A I N L A N G U A G E S U M M A R Y
Administration of prostaglandins to pregnant women before caesarean section to prevent breathing difficulties in newborn babies
Respiratory difficulties in newborn babies are a common complication following birth. They are more frequent with caesarean section and when the pregnant woman is operated on before labour starts than when she is in labour. Prostaglandins are a group of substances that have been used successfully to induce labour in pregnant women. They also have the potential to help the lungs of the newborn to adapt to breathing air after delivery, by removing fluid from the lungs and increasing surfactant secretion. Caesarean sections are performed more frequently worldwide and it is important to find interventions that improve the newborn's breathing following this surgery.
We found one small randomised trial (involving 36 women) that compared prostaglandin E 2 intravaginal gel administered before caesarean section compared with a placebo gel. The information obtained from this study did not permit us to be certain that prostaglandins improve neonatal breathing following planned caesarean section at term. Only one baby in the placebo group had respiratory distress assessed as rapid breathing. Further studies have to be carried out in order to find out the impact of prostaglandins on the newborn lungs after caesarean section.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prostaglandin E2 versus placebo before caesarean section for prevention of neonatal respiratory distress There was no reported neonatal death in the study.
M aternal adverse events
Study population
Not estim able 36 (1 study)
There was no m aternal adverse event reported in the study. See com m ent See com m ent * The basis f or the assumed risk (e.g. the m edian control group risk across studies) is provided in f ootnotes. The corresponding risk (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). CI: Conf idence interval; RR: Risk ratio;
GRADE Working Group grades of evidence High quality: f urther research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: f urther research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate. Low quality: f urther research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: we are very uncertain about the estim ate.
1 The optim al inf orm ation size was not m et, conf idence intervals were wide and event rates were low. 
B A C K G R O U N D
Description of the intervention
Prostaglandins are used in obstetrics for cervical ripening and induction of labour with good results (Hofmeyr 2003; Witter 1992 
How the intervention might work
Decades ago, it was suggested that poor respiratory outcomes in infants delivered by elective CS may be explained by delayed absorption of liquid in the lung due to lack of a catecholamine surge (Faxelius 1983) . Studies in animals during spontaneous or oxytocin-induced labour show an association between an increase in plasma epinephrine and reduced production and increased absorption of lung liquid. It is known that prostaglandin E 2 stimulates production of surfactant in fetal lungs as term approaches (Torday 1998). Furthermore, the concentration of beta-adrenergic receptors in lung tissue is known to increase late in gestation, which might render the lungs more responsive to the effects of epinephrine (Bland 2008 
Why it is important to do this review
A study evaluating metabolic adaptation in the newborn revealed that infants delivered per vagina showed high catecholamine levels at birth compared with infants born by CS under epidural or general anaesthesia (Hägnevik 1984) . Prostaglandins can stimulate surfactant secretion and reduce lung fluid by provoking a catecholamine surge (Singh 2004) and therefore significantly reducing neonatal respiratory morbidity following a CS. This could eventually reduce long-term complications such as bronchopulmonary dysplasia (Bland 2008), which results from prolonged ventilation in severe RDS and asthma, which develops more frequently in children aged zero to four years with a history of TTN (Whitsett 2005) . It is important to collect and summarise evidence of the use of prostaglandins for improving fetal respiratory outcomes.
O B J E C T I V E S
To determine if the administration of prostaglandins before caesarean section improves the respiratory outcomes of newborns.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials and if unavailable, quasi-randomised controlled trials comparing the use of prostaglandins with other treatments (including placebo) to reduce neonatal respiratory morbidity.
Types of participants
All pregnant women with an indication for a caesarean section.
Types of interventions
Administration of prostaglandins prior to caesarean section compared with no treatment, placebo or another treatment.
Types of outcome measures
Primary outcomes 1. Incidence of respiratory distress in neonates: respiratory distress will be considered as defined by the authors.
2. Need for mechanical ventilation of the neonate: this could be the Ambu resuscitator or endotracheal intubation.
3. Apgar score of newborn: the Apgar score is usually used to represent the neonate's ability to initiate and maintain breathing after birth on a scale from zero to 10. It is measured at the first and fifth minute of life. Apgar scores less than three indicate severe respiratory depression and scores from four to six indicate mild to moderate respiratory depression. There is no respiratory depression when the scores are from seven to 10 (Apgar 1953; Harrison 2008).
Secondary outcomes
Maternal outcomes
We included all adverse events reported by the study authors.
Fetal outcomes
1. Catecholamine levels in the neonate. 2. Neonatal arterial oxygen, carbon dioxide partial pressures and fetal scalp pH measurements.
3. All cause fetal mortality: any death that occurs from the time the neonate is included in the study.
4. Proportion of neonates requiring admission into an intensive care unit.
5. Length of stay in neonatal intensive care unit. 6. Long-term complications related to respiratory distress. 7. Any other adverse event reported by the authors.
Search methods for identification of studies Electronic searches
We 5. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the Cochrane Pregnancy and Childbirth Group. Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. In addition, to the search carried out by the Trials Search Coordinator, we searched ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry and the WHO Clinical Trials Registry Platform (ICTRP), for ongoing studies. Last searched 24 June 2013 (see Appendix 1). We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors (NM and LM) independently assessed identified studies for inclusion. We resolved disagreements through discussion.
Data extraction and management
We used a pre-designed and tested data extraction form to collect data from the eligible studies. Data were extracted in duplicate using the agreed form. We resolved discrepancies through discussion. We entered data into Review Manager software (RevMan 2011) and checked for accuracy. Some information regarding the only included study was unclear and we attempted to contact authors of the original reports to provide further details but did not obtain any response from them.
Assessment of risk of bias in included studies
Two review authors (NM, LM) independently assessed risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved all disagreement by discussion.
(1) Random sequence generation (checking for possible selection bias)
We described for the single included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We assessed the method as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for the single included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias. We described for the single included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel. We described for the single included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)
We described for the single included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses which we undertook. We assessed the methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation. We intended to consider studies with more than 20% missing data as high risk of bias);
(5) Selective reporting (checking for reporting bias)
We described for the single included study how we investigated the possibility of selective outcome reporting bias and what we found.
• low risk of bias (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);
• high risk of bias (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We described for the single included study any important concerns we had about other possible sources of bias.
We assessed whether the study was free of other problems that could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether the study was at high risk of bias, according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We planned to explore the impact of the level of bias by undertaking sensitivity analyses -see Sensitivity analysis.
Assessment of quality of evidence across studies
We assessed the quality of the body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) (Guyatt 2008) , defining the quality of evidence for each outcome as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest (Higgins 2011). The quality rating across studies has four levels: high, moderate, low or very low. Randomised controlled trials are categorised as high quality but can be downgraded; similarly, other types of controlled trials and observational studies are categorised as low quality but can be upgraded. Factors that decrease the quality of evidence include limitations in design, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or high probability of publication bias. Factors that can increase the quality level of a body of evidence include having a large magnitude of effect, whether plausible confounding would reduce a demonstrated effect, and if there is a dose-response gradient.
Measures of treatment effect Dichotomous data
We presented our results as summary risk ratio with 95% confidence intervals for dichotomous data. However, there were no events for some outcomes therefore, we applied a correction of 0.5 in order to calculate the risk ratio.
Continuous data
For continuous data, we intended to use the mean difference where outcomes were measured in the same way between trials and the standardised mean difference to combine trials that measured the same outcome, but used different methods. Data obtained from the single included study did not permit us to do so and we thus reported medians and interquartile ranges in the text.
Unit of analysis issues
We did not identify any cluster-randomised trials for inclusion in this review. However, if we identify cluster-randomised trials in future updates of this review we will include them in the analyses along with individually-randomised trials. We will adjust their sample sizes using the methods described in the Cochrane Handbook using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.
Dealing with missing data
For the single included study, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We planned to assess statistical heterogeneity in each meta-analysis using the Tau-squared (T²), I² and Chi-squared (X²) statistics, regarding heterogeneity as substantial if an I² was greater than 30% and either a T² was greater than zero, or there was a low P value (less than 0.10) in the X² test for heterogeneity. There was one included study which did not allow for any meta-analysis or analysis of heterogeneity.
Assessment of reporting biases
In future, updates of this review, if there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager software (RevMan 2011). This review contains one included study and thus, we could not combine data in meta-analysis. In future updates of this review, we will use fixed-effect metaanalysis for combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect: i.e. where trials are examining the same intervention, and the trials' populations and methods are judged sufficiently similar. If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials is considered clinically meaningful. The randomeffects summary will be treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We did not carry out our prespecified subgroup analyses due to insufficient data. We plan to carry out the following subgroup analysis in future updates of this review. 1. Preterm neonates versus term neonates. 2. Emergency CS versus elective CS. 3. Various types of prostaglandins used. If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful and use random-effects analysis to produce it. We will assess subgroup differences by interaction tests available within RevMan (RevMan 2011). We will report the results of subgroup analyses quoting the χ2 statistic and P value, and the interaction test I² value.
Sensitivity analysis
Planned sensitivity analysis was not carried out due to insufficient data. In future updates, sensitivity analysis will be carried out to explore the effect of trial quality, including studies assessed as having adequate controls in place for the prevention of potential bias.
R E S U L T S Description of studies
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group's Trials Register retrieved two reports. After verification, we realised that these were two reports of the same trial. We did not find any ongoing studies in the following trial registries: ClinicalTrials.gov, the Australian New Zealand Clinical Trials Registry and the WHO Clinical Trials Registry Platform (ICTRP) (see: Figure 1 ).
Figure 1. Study flow diagram
Included studies
We included one randomised controlled trial in this review that compared prostaglandin E 2 with placebo (Singh 2004). It was a randomised placebo-controlled study that was carried out in a tertiary regional neonatal care centre in Australia. There were 36 participants, 18 in the intervention and 18 in the control group. Participants were pregnant women at term with an indication for elective caesarean section (ECS). Excluded from the study were: pregnancies with known fetal malformation/s or chromosomal aberration, presence of absolute contraindications for use of prostaglandin E2 vaginal gel, for example, history of adverse reactions to prostaglandin preparations, ECS deliveries before 38 weeks' gestation and failure to obtain informed consent. The study compared 2 mg of prostaglandin E 2 gel with placebo (K-Y jelly) when administered as intravaginal gel 60 minutes prior to ECS. The aim of the study was to compare catecholamine levels in neonatal cord blood between the prostaglandin E 2 group and the placebo group. Other outcomes assessed included Apgar score at one and five minutes, neonatal respiratory distress, admission into a neonatal special care, arterial and venous pH measurements.The study authors used non-parametric tests (MannWhitney-Wilcoxon test and Fisher's exact test) to compare both groups. P values were reported. Baseline characteristics: the baseline characteristics of participants in the intervention and control groups were similar. These included the age of the mother, gestational age, Bishop score, parity, previous caesarean section (CS), cervical dilatation, time to delivery following prostaglandin administration and type of anaesthesia used during the CS.
Excluded studies
There were no excluded studies.
Risk of bias in included studies
We assessed the risk of bias in the included study using the Cochrane 'Risk of bias' tool for randomised controlled trials (Figure 2) . 
Allocation
Allocation of participants to receive either the intervention or control was done using computer-generated random numbers. It was not specified if block randomisation was used but there were equal numbers in each arm. The allocation sequence was concealed using sequentially numbered opaque envelopes.
Blinding
Enrolled participants received an equal volume of prostaglandin E 2 or K-Y jelly as intravaginal gel ensuring adequate blinding of participants. Adequate blinding of the primary investigators, as well as the medical teams in charge of the mother and neonate was done. An independent research assistant was in charge of opening the sealed envelopes and administering the drug or placebo to the participants.
Incomplete outcome data
There was one participant in the control group for whom no data were reported after randomisation. However, this did not represent any significant differential loss to follow-up.
Selective reporting
The investigators reported all the outcomes specified in the manuscript. We were unable to find a published manuscript of the protocol for this study.
Other potential sources of bias
We did not identify any other potential source of bias.
Effects of interventions
See: Summary of findings for the main comparison Prostaglandin E2 Administered Before Caesarean Section for Prevention of Neonatal Respiratory Distress The included study reported the following outcomes: respiratory distress, need for mechanical ventilation, Apgar score of newborns, neonatal catecholamine levels, neonatal blood pH, mortality, admission into an intensive care unit and adverse events. The continuous outcomes were reported as medians and interquartile ranges. Hence, the data could not be added to the data and analysis tables and are re-reported from the original trial report. This review had a number of other prespecified outcomes that were not reported in the included study: neonatal arterial oxygen, carbon dioxide partial pressures, length of stay in neonatal intensive care unit, and long-term complications related to respiratory distress.
Primary outcomes
Incidence of respiratory distress in the neonate
There was one case of neonatal respiratory distress in the control group which the authors (Singh 2004) reported as transient tachypnoea of the newborn (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.01 to 7.68, one study, n = 36 (Analysis 1.1)).
Need for mechanical ventilation of the neonate
None of the neonates required mechanical ventilation.
Apgar score of the newborn
Apgar score was reported at one and five minutes with the median (interquartile range) score being nine (eight to nine) and 9.5 (nine to 10) respectively for the intervention group. For the control group, the scores were nine (nine to nine) at one minute and nine (nine to nine) at five minutes.
Secondary outcomes Catecholamine levels in the neonate
Catecholamine levels in the neonate were reported as median values (interquartile range). Neonatal noradrenaline concentrations were reported as being significantly higher in the intervention group with respect to the control group, with measurements of 15.0 ng/L (9.8 to 28.92) and 4.6 ng/L (1.65 to 14.4) respectively (P = 0.03). The concentrations of adrenaline did not vary significantly between groups; 1.6 ng/L (below 0.5 to 3.1) for intervention group and 1.4 ng/L (below 0.5 to 2.75) for placebo group (P = 0.6).
Neonatal pH measurements
Arterial and venous pH measurements were similar in both intervention and control groups and were reported as median values (interquartile range). Arterial pH was 7.31 (7.28 to 7.37) for the intervention group and 7.31 (7.29 to 7.33) for the control group (P = 0.70). Venous pH measurements for intervention and control groups were 7.36 (7.34 to 7.39) and 7.37 (7.32 to 7.44) respectively (P = 0.89).
All cause fetal mortality
There were no deaths in the study population.
Proportion of neonates requiring admission into intensive care unit
No neonate was admitted into an intensive care unit.
Any other adverse event reported by the authors
The trialist reported that there were no treatment-related side effects reported in either group.
D I S C U S S I O N
Summary of main results
There were 36 women in the one included study, 18 received intravaginal prostaglandin E 2 gel and 18 received placebo. One neonate in the control group developed respiratory distress, reported as transient tachypnoea of the newborn by the authors. None of the neonates required mechanical ventilation and the Apgar scores at one and five minutes where similar in both groups. Although no admissions to neonatal intensive care occurred, two neonates in the control group were admitted into special care. No further information was provided on the reasons for these admissions. Outcomes indicating respiratory status did not differ significantly between intervention and control groups and there was no treatment-related side effects. Noradrenaline concentrations were significantly higher in the cord blood samples of the intervention group.
Overall completeness and applicability of evidence
The only significant difference in outcomes reported was in noradrenaline measurements in neonatal cord blood. Although being a catecholamine, adrenaline measurements did not differ significantly between groups. The authors related this to the type of assay used to measure catecholamine concentrations in the study.
Other indicators of neonatal respiratory well-being such as respiratory distress, mechanical ventilation, admission to special care and blood gas measurements did not differ between groups. The evidence from this review is drawn from a single small study and hence, may not be generalisable to other populations of pregnant women.
Quality of the evidence
We used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) (Guyatt 2008) approach for grading the quality of evidence in this review (Higgins 2011) . We carried out one comparison: prostaglandin E 2 versus placebo before ECS for improving respiratory outcomes of the newborn at term. Given that the included study was a randomised controlled trial, we started at very high-quality evidence and we downgraded by two points for imprecision. We did not downgrade for risk of bias, inconsistency, indirectness and publication bias. We determined that there was low-quality evidence to determine if prostaglandins administered before caesarean could prevent neonatal respiratory distress.
Potential biases in the review process
We were able to identify one randomised controlled trial (Singh 2004) using the comprehensive search strategy of the Cochrane Pregnancy and Childbirth Group which did not use any language limitations. We went further and searched three clinical trial registries and did not find any ongoing trials. It is possible, although unlikely that other trials have been conducted but not published, evaluating the effects of prostaglandins on neonatal respiratory outcomes. Other biases were limited by conducting the data extraction and quality assessment in duplicate.
Agreements and disagreements with other studies or reviews
Studies in animals have demonstrated the effects of catecholamines on fetal lung adaptation to extra-uterine life (Torday 1998; Zaremba 1997). We found no reviews, trials or observational studies in humans involving the use of prostaglandins for the purpose of improving neonatal respiratory outcomes. As a result, we cannot compare the results we derived from this review to other studies.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Although the trial authors reported a significant increase in catecholamine levels in the intervention group, there was no significant difference in the respiratory outcomes between intervention and control groups. No definite conclusions can thus be drawn on the effects of prostaglandins on neonatal respiratory outcomes from this review due to the nature of the evidence available.
Implications for research
Caesarean sections are increasingly performed worldwide, leading to an increase in the number of neonates at risk of respiratory distress (RD). It is important to develop interventions that prevent neonatal RD and its consequences. The study included in this review involved only prostaglandin E 2 vaginal gel and had a small sample size, therefore larger studies are required for better assessment of the impact of this intervention. Furthermore, the role of prostaglandins in situations such as emergency caesarean section and preterm neonates has to be defined,as well as the use of different dose regimens and routes of administration.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Singh 2004
Methods Randomised placebo controlled trial. The trial was carried out in a regional tertiary neonatal centre in Australia 
A P P E N D I C E S Appendix 1. Search terms for clinical trial registries
Caesarean, prostaglandin, neonatal respiratory distress. The search combination used was (Caesarean AND prostaglandin AND neonatal respiratory distress) (Authors wrote and ran this search)
